Adherence to antiretroviral therapy, virological response, and time to resistance in the Dakar cohort

Statistics in Medicine

Volumn 29, Issue 1, 2010, Pages 14-32

  Tournoud, M ^a,b   Etard, J F ^b   Ecochard, R ^c,d   Degruttola, V ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^c HOSPICES CIVILS DE LYON   (France)

^d UNIVERSITÉ LYON 1   (France)

Author keywords

Adherence to antiretroviral therapy; Bayesian prediction; Joint models; Resistance mutations; Virological failure

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ARTICLE; BAYES THEOREM; HEALTH CARE ACCESS; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; LOW DRUG DOSE; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PREDICTION; PROBABILITY; SENEGAL; STATISTICAL MODEL; STATISTICAL PARAMETERS; SURVIVAL RATE; TREATMENT RESPONSE; VIRUS MUTATION; VIRUS RESISTANCE;

EID: 74849103260     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.3779     Document Type: Article

References (29)

1. Bowles E, Wensing A, van de Vijver D, Boucher C. Global transmission of resistant HIV-1: geographical patterns may reflect differences in introduction and use of antiretroviral drugs. Reviews in Antiviral Therapy 2006; 4:47.
2. Hammer SM, Saag MS, Schechter M, Montaner JSG, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CCJ, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. Journal of the American Medical Association 2006; 296:827-843. DOI: 10.1001/jama.296.7.827.
3. Hernan MA, Hernandez-Diaz S, Robins JM. A structural approach to selection bias. Epidemiology 2004; 15:615-625.
4. Yu M, Law N, Taylor J, Sandler H. Joint longitudinal survival cure models and their applications to prostate cancer. Statistica Sinica 2004; 14:835-862.
5. Tsiatis A, Davidian M. Joint modeling of longitudinal and time-to-event data: an overview. Statistica Sinica 2004; 14:809-834.
6. Hu C, De Gruttola V. Joint modeling of progression of HIV resistance mutations measured with uncertainty and failure time data. Biometrics 2007; 63:60-68. DOI: 10.1111/j.1541-0420.2006.00635.x.
7. Yu M, Taylor J, Sandler H. Individual prediction in prostate cancer studies using a joint longitudinal survival cure model. Journal of the American Statistical Association 2008; 103:178-187.
8. Huang W, De Gruttola V, Fischl M, Hammer S, Richman D, Havlir D, Gulick R, Squires K, Mellors J. Patterns of plasma human immunodeficiency virus type 1 RNA response to antiretroviral therapy. Journal of Infectious Diseases 2001; 183:1455-1465. DOI: 10.1086/320192.
9. Lucas GM. Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven. The Journal of Antimicrobial Chemotherapy 2005; 55:413-416. DOI: 10.1093/jac/dki042.
10. Etard JF, Lanièce I, Fall MBK, Cilote V, Blazejewski L, Diop K, Desclaux A, Ecochard R, Ndoye I, Delaporte E. A 84-month follow up of adherence to HAART in a cohort of adult Senegalese patients. Tropical Medicine and International Health 2007; 12:1191-1198. DOI: 10.1111/j.1365-3156. 2007.01910.x.
11. Gross R, Yip B, Re III V, Wood E, Alexander C, Harrigan P, Bangsberg D, Montaner J, Hogg R. A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain hiv-1 suppression. The Journal of Infectious Diseases 2006; 194:1108-1114. DOI: 10.1086/507680.
12. Paterson D, Swindells S, Mohr J, Brester M, Vergis E, Squier C, Wagener M, Singh N. Adherence to protease inhibitor therapy and outcomes in patients with hiv infection. Annals of Internal Medicine 2000; 133:21-30.
13. Orrell C, Bangsberg D, Badri M, Wood R. Adherence is not a barrier to successful antiretroviral therapy in south Africa. AIDS 2003; 17:1369-1375. DOI: 10.1097/01.aids.0000060398.18106.f6.
14. Carrieri M, Leport C, Protopopescu C, Cassuto J, Bouvet E, Peyramond D, Raffi F, Moatti J, Cheêne G, Spire B. Factors associated with nonadherence to highly active antiretroviral therapy: a 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase. JAIDS Journal of Acquired Immune Deficiency Syndromes 2006; 41:477-485. DOI: 10.1097/01.qai.0000186364.27587.0e.
15. Rubio M, Pedeboscq S, Ekouevi D, Zalabadi K, Chene G, Bonarek M, Pometan J. The adherence to antiretroviral treatment evaluated from a hospital pharmacy: importance of the protease inhibitors pharmacological class. International Journal of STD and AIDS 2005; 16:379-382. DOI: 10.1258/ 0956462053888826.
16. King J, Wynn H, Brundage R, Acosta E. Pharmacokinetic enhancement of protease inhibitor therapy. Clinical Pharmacokinetics 2004; 43:291-310.
17. Gelfand A, Smith A. Sampling-based approaches to calculating marginal densities. Journal of the American Statistical Association 1990; 85:398-409.
18. Gelman A, Carlin J, Stern H, Rubin D. Bayesian Data Analysis (2nd edn). Chapman & Hall: London, 2004.
19. Spiegelhalter D, Thomas A, Best N, Lunn D. Winbugs version 1.4 user manual. Technical Report, 2003. Available from: http://www.mrcbsu.cam.ac. uk/bugs/winbugs/manual14.pdf.
20. Brooks S, Gelman A. General methods for monitoring convergence of iterative simulations. Journal of Computational and Graphical Statistics 1998; 7:434-455.
21. Turnbull B. The empirical distribution function with arbitrarily grouped, censored and truncated data. Journal of the Royal Statistical Society, Series B (Methodological) 1976; 38:290-295.
22. Laurent C, Diakhaté N, Gueye NFN, Touré MA, Sow PS, Faye MA, Gueye M, Lanièce I, Touré Kane C, Liégeois F, Vergne L, Mboup S, Badiane S, Ndoye I, Delaporte E. The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS 2002; 16:1363-1370.
23. Etard JF, Ndiaye I, Thierry-Mieg M, Guèye NFN, Guèye PM, Lanièce I, Dieng AB, Diouf A, Laurent C, Mboup S. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 2006; 20:1181-1189. DOI: 10.1097/01.aids.0000226959.87471.01.
24. World Health Organization (WHO). Antiretroviral therapy for hiv infection in adults and adolescents: recommendations for a public health approach. Technical Report, 2006. Available from: http://www.who.int/hiv/pub/ guidelines/artadultguidelines.pdf.
25. Yakovlev A, Asselain B, Bardou V, Fourquet A, Hoang T, Rochefediere A, Tsodikov A. A simple stochastic model of tumor recurrence and its application to data on premenopausal breast cancer. Biométrie et Analyse de Données Spatio-Temporelles 1993; 12:67-82.
26. Tournoud M, Ecochard R. Application of the promotion time cure model with time-changing exposure to the study of HIV/AIDS and other infectious diseases. Statistics in Medicine 2007; 26:1008-1821. DOI: 10.1002/sim.2590.
27. Friedland G, Williams A. Attaining higher goals in HIV treatment: the central importance of adherence. AIDS 1999; 13(Suppl 1):S61-S72.
28. Gilks WR. Derivative-free adaptive rejection sampling for Gibbs sampling. Bayesian Statistics 1992; 4:169-194.
29. Gilks WR, Best NG, Tan KKC. Adaptive rejection metropolis sampling. Applied Statistics 1995; 44:455-472.